These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19001165)

  • 21. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased Pittsburgh Compound-B Accumulation in the Subcortical White Matter of Alzheimer's Disease Brain.
    Wakabayashi Y; Ishii K; Hosokawa C; Hyodo T; Kaida H; Yamada M; Yagyu Y; Tsurusaki M; Kozuka T; Sugimura K; Murakami T
    Kobe J Med Sci; 2017 Mar; 62(5):E136-E141. PubMed ID: 28289271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship Between PET-Assessed Amyloid Burden and Visual and Verbal Episodic Memory Performance in Elderly Subjects.
    Squarzoni P; Faria DP; Yassuda MS; Porto FHG; Coutinho AM; Costa NAD; Nitrini R; Forlenza OV; Duran FLS; Brucki SMD; Buchpiguel CA; Busatto GF
    J Alzheimers Dis; 2020; 78(1):229-244. PubMed ID: 32986673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.
    Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA
    Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease.
    Kemppainen NM; Aalto S; Karrasch M; Någren K; Savisto N; Oikonen V; Viitanen M; Parkkola R; Rinne JO
    Ann Neurol; 2008 Jan; 63(1):112-8. PubMed ID: 18023012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication.
    Remes AM; Laru L; Tuominen H; Aalto S; Kemppainen N; Mononen H; Någren K; Parkkola R; Rinne JO
    Arch Neurol; 2008 Apr; 65(4):540-4. PubMed ID: 18413480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of [
    Lowe VJ; Lundt E; Knopman D; Senjem ML; Gunter JL; Schwarz CG; Kemp BJ; Jack CR; Petersen RC
    Neuroimage Clin; 2017; 16():295-302. PubMed ID: 28856092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures.
    Apostolova LG; Hwang KS; Avila D; Elashoff D; Kohannim O; Teng E; Sokolow S; Jack CR; Jagust WJ; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neurology; 2015 Feb; 84(7):729-37. PubMed ID: 25609767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition.
    Schultz SA; Boots EA; Almeida RP; Oh JM; Einerson J; Korcarz CE; Edwards DF; Koscik RL; Dowling MN; Gallagher CL; Bendlin BB; Christian BT; Zetterberg H; Blennow K; Carlsson CM; Asthana S; Hermann BP; Sager MA; Johnson SC; Stein JH; Okonkwo OC
    J Int Neuropsychol Soc; 2015 Nov; 21(10):841-50. PubMed ID: 26581795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.
    Murray ME; Lowe VJ; Graff-Radford NR; Liesinger AM; Cannon A; Przybelski SA; Rawal B; Parisi JE; Petersen RC; Kantarci K; Ross OA; Duara R; Knopman DS; Jack CR; Dickson DW
    Brain; 2015 May; 138(Pt 5):1370-81. PubMed ID: 25805643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
    Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.
    Koivunen J; Karrasch M; Scheinin NM; Aalto S; Vahlberg T; Någren K; Helin S; Viitanen M; Rinne JO
    Dement Geriatr Cogn Disord; 2012; 34(1):31-7. PubMed ID: 22868352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease.
    Hamelin L; Lagarde J; Dorothée G; Potier MC; Corlier F; Kuhnast B; Caillé F; Dubois B; Fillon L; Chupin M; Bottlaender M; Sarazin M
    Brain; 2018 Jun; 141(6):1855-1870. PubMed ID: 29608645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
    Babulal GM; Ghoshal N; Head D; Vernon EK; Holtzman DM; Benzinger TLS; Fagan AM; Morris JC; Roe CM
    Am J Geriatr Psychiatry; 2016 Nov; 24(11):1095-1104. PubMed ID: 27426238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study.
    Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Kosaka J; Kudo T; Iida H; Kishimoto T; Nagatsuka K
    Int J Geriatr Psychiatry; 2016 Aug; 31(8):920-8. PubMed ID: 26766490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.